Compare BioNano Genomics Inc (BNGO) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Cenovus Energy Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Cenovus Energy Inc trades at $29.91 (market cap $55.00B). The key difference: Cenovus Energy Inc is far larger — about 4026.4× BioNano Genomics Inc's market cap, and Cenovus Energy Inc pays a 2.09% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | CVE | |
|---|---|---|
Market Cap | $13.66M | $55.00B |
Sector | Health | Energy |
52-Week High | $4.92 | $31.80 |
52-Week Low | $1.06 | $14.83 |
Enterprise Value | $16.26M | $61.08B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Cenovus Energy (CVE) trades at $30.14, up 1.96% with bullish technical signals and strong fundamentals. The stock shows robust earnings momentum with recent quarterly beats, supported by record oil sands production and disciplined cost management. Valuation metrics remain attractive with P/E of 11.56 and EV/EBITDA of 5.77, while profitability metrics include 11.48% net income margin and 20.96% ROE. Recent news highlights institutional buying interest and strong Q2 2026 operational performance.
CVE presents a compelling investment case with undervalued metrics and positive earnings trajectory, though exposure to volatile oil prices and refining margins poses risks. Analyst consensus leans bullish with 40.7% buy ratings, while technical indicators suggest continued upward momentum. The company's integrated model and growth projects support long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
